Intellectia LogoIntellectia
Product
Resources
Stock
Crypto
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategy
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns

Resources

Learn
Blog
Earnings
Tutorial
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
StockCryptoPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CING
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
CING
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

CING Similar Chart Price Prediction

The price of CING is predicted to go up -29.78%, based on the high correlation periods with VCSA. The similarity of these two price pattern on the periods is 94.33%.

stocks logo

CING

stocks logo

VCSA

Down: -29.78%Similarity: 94.33%

CING Revenue Forecast

CING EPS Forecast

CING FAQs

What is bull’s view on CING?

CING stock is currently trading around $8.20, with a bullish outlook driven by its Precision Timed Release (PTR) technology for ADHD treatment. Analysts have set aggressive price targets, including $20 (HC Wainwright) and $12 (Roth MKM), citing strong Phase 3 data and potential $1.6B sales by 2035. The stock's recent momentum, coupled with reduced short interest, supports further upside potential.

What is bear's view on CING?

CING stock is bearish due to its recent dilution concerns and volatile trading patterns. Despite a $20 price target from HC Wainwright, the stock's current price of $8.2 reflects skepticism about near-term growth. The bearish view is reinforced by potential dilution risks and reliance on future milestones like CTx-1301's mid-2025 filing.

What is CING eps forecast for next quarter？

The market consensus for CING's eps in the upcoming quarter is projected to be approximately $1.64 USD.

CING VS S&P500

Ask Intellectia about CING

CING Analyst's Forecast

Boobalan Pachaiyappan

Roth MKM

Strong Buy

2025-01-10

Price Target

$12

Upside

+149.48%

Roth MKM initiated coverage of Cingulate with a Buy rating and $12 price target. The firm's optimism is driven by CTx-1301's Phase 3 data demonstrating entire active day efficacy in ADHD patients with an "industry-leading" average effect size. The company's current pro forma cash position and potential near-term dilution could be balanced by CTx-1301's new drug filing in mid-2025 and the potential to garner $1.6B in sales in 2035, the analyst tells investors in a research note.
Naz Rahman

Maxim Group

Hold → Strong Buy

2024-11-20

Price Target

n/a

Downside

0%

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI Screener
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free

Hot Stocks

stocks logo

ATGE

Adtalem Global Education Inc

$102.31
2.24%
stocks logo

HAE

Haemonetics Corp

$65.5
1.44%
stocks logo

ALIT

Alight Inc

$6.83
0.89%
stocks logo

SHC

Sotera Health Co

$12.47
1.55%
stocks logo

APLS

Apellis Pharmaceuticals Inc

$25.15
-3.27%
stocks logo

RUSHA

Rush Enterprises Inc

$58.32
0.55%
stocks logo

GFF

Griffon Corp

$72.34
1.25%
stocks logo

NPO

Enpro Inc

$182.08
-2.11%
stocks logo

WRD

WeRide Inc

$19.95
0.61%
stocks logo

RUM

Rumble Inc

$9.32
1.53%